A Corporate Battle with Industry-Wide Consequences
The Pfizer v. Metsera case may redefine how Big Pharma handles hostile counteroffers and antitrust scrutiny in the emerging obesity drug gold rush.
For now, Pfizer’s lawsuit—“Pfizer Sues Metsera”—signals that the company is unwilling to yield ground in what could become one of the decade’s fiercest pharmaceutical battles.
